RE: häufige HNO-Infektionen
hallo,
die kiga these kann ich aus einer vielzahl eigener erfahrungen nur bestaetigen und halte sie fuer sehr plausibel - ob sie nun mit einem jahr oder 3 jahren in die kiga einrichtung kommen - das erste jahr ist sehr oft ein sehr strapazioeses fuer die betroffenen kinder und eltern.
Luivac gehoert zu den sog. polyvalenten bakteriellen zell-lysaten. ich persoenlich habe keine praktischen erfahrungen damit. erreicht werden soll eine erhoehte immunitaet gegen die antigene des lysates und damit ein verbesserter immunschutz vor erkaeltungskrankheiten.
2 publikationen:
Use of a Polyvalent Bacterial Lysate in Patients With Recurrent Respiratory Tract Infections: Results of a Prospective, Pacebo-Controlled, Randomized, Double-Blind Study
Rutishauser et al.
Advances In Therapy Volume 15 No. 6 (1998)
ABSTRACT
Respiratory tract infections (RTIs) are the most common infections in humans, and it is difficult to effectively treat patients with increased susceptibility to these ailments. LW 50020 (Luivac®; Paspat® oral), an oral immunomodulator consisting of the antigens of seven bacteria commonly involved in RTIs, has been developed for the induction of specific and nonspecific immune responses of the mucosa-associated lymphoid tissue. In this placebo-controlled study, the efficacy and safety of the tablet formulation of LW 50020 were evaluated in children and adults with recurrent RTIs. Tablets were taken once daily during two periods of 4 weeks each, interrupted by a treatment-free interval of 4 weeks. The main endpoint of the study, a clinical severity score that evaluated treatment benefits, was significantly lower in the second study period in patients treated with the bacterial lysate compared to patients given placebo. A comparsion of the infection rates in the first and second study periods of patients treated with LW 50020 revealed a placebo-corrected reduction of 39% in children and a placebo-corrected reduction of 44% in adolecents and adults. The placebo-corrected duration of infections was shortened by 47% in children and by 55% in older patients. No serious drug-related side effects occurred. This study demonstrated that the oral bacterial immunomodulator LW 50020 is efficacious in treating patients with recurrent RTIs.
und
Treatment of Recurrent Respiratory Tract Infections With a Polyvalent Bacterial Lysate: Results of an Open, Prospective, Multinational Study
Grevers et al.
Advances In Therapy Volume 17 No. 2 (2000)
ABSTRACT
This multicenter, open study, carried out in 14 countries in Europe, Latin America, and Asia, recruited 4965 patients suffering from recurrent respiratory tract infections to investigate the safety and acceptability of the oral bacterial lysate immunomodulator LW 50020. Patients remained in the study for 4 months (two 4-week courses of LW 50020 separated by a 28-day treatment-free interval and follow-up). The incidence of all adverse events was 7.2%; that of adverse drug reactions was 0.6%. Adverse drug reactions were mild to moderate and not more frequent in the large subgroup of patients (77%) with a known history of allergies or underlying respiratory diseases; however, the incidence of adverse events in this subgroup was twofold higher than in the study population as a whole, probably indicating a generally increased vulnerability to disease. No clinically relevant changes in laboratory variables followed treatment. Comparison of the first study period (first course of LW 50020 and drug-free interval) with the second study period (second course of LW 50020 and follow-up) showed an overall reduction of at least 50% in the number, severity, and duration of respiratory tract infections, the number of antibiotic and symptomatic treatments, and the number of days absent from school or work. Tolerability and acceptability were assessed as good or very good in 99% of patients who completed the study.
habe ich gefunden.
wie gut sie sind, kann man nur nach dem lesen beurteilen.
nun, die meisten erkaeltungskrankheiten beginnen viral.
dagegen hilft das medikament schon mal nicht.
bei schweren verlaeufen gibt es aber auch oft superinfektionen mit bakteriellen erregern.
da bestuende die moeglichkeit, dass das praeparat wirken koennte, so denn die orale gabe eine entsprechende immunitaet verleiht und dieselben antigene vorhanden sind.
alles in allem kann man sicher nicht zuviel falsch machen.
ueber die wirkung kann man sicher streiten.
allerdings waere es sehr hilfreich, die genaue zusammensetzung des praeparates zu kennen.
ich wuensch euch alles gute und es waere schoen, mal eine rueckkopplung zu haben, wie das medikament nach eurer meinung gewirkt hat!